C4 THERAPEUTICS PRESENTS NEW BIOMARKER DATA FROM THE CEMSIDOMIDE PHASE 1 TRIAL WITH DEXAMETHASONE AND PHASE 1B TRIAL WITH ELRANATAMAB (ELREXFIO®) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA AT THE 23RD INTERNATIONAL MYELOMA SOCIETY (IMS) ANNUAL MEETING

Reuters · 2d ago

Please log in to view news